Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Mary-Claire King at the European Society for Human Genetics 2016

Her vision of genomic medicine as a dialogue at ESHG 2016 in Barcelona, Spain

Posted by Dale Yuzuki on Jun 6, 2016 3:29:24 PM

Mary-Claire King is Professor of Genome Sciences and of Medicine (Medical Genetics) at the University of Washington (Seattle, WA), who first described a single gene on chromosome 17q21 (which she named BRCA1) being responsible for breast and ovarian cancer in many families. This work, published in Science in 1990, also revolutionized the study of many other common, single-gene diseases that are inherited in nature, and led to the discovery of BRCA2. 

 

Read More

Topics: Cancer, Inherited Disease, Oncology

SeraCare introduces AccuPlex™ Zika Reference Material

Recombinant viral technology to assist development of PCR-based Zika Virus diagnostic assays

Posted by Dale Yuzuki on May 10, 2016 9:00:00 AM

Guest author: Han Joo Lee, Ph.D., SeraCare Technical Product Manager

A cursory look at recent Zika Virus outbreak news headlines is alarming enough: “Zika Virus birth defects may be the ‘Tip of the Iceberg’, experts say”; “Brain damage in Zika babies is far worse than doctors expected”; and “Zika mutates extremely quickly, which is why it’s so scary”. In addition, for the United States the estimated range maps of the Aedes aegypti and Aedes albopictus have been recently updated, widening the range previously reported to all but 10 states within the US.

Read More

Topics: Accuplex, Genomics, viral technology, zika virus

American Association for Cancer Research 2016 ctDNA highlights

Circulating tumor DNA, along with immunotherapy, are two major themes of #AACR16

Posted by Dale Yuzuki on May 2, 2016 9:00:00 AM

At the American Association for Cancer Research conference recently held in New Orleans, LA (April 16 - April 20, 2016) one theme that generated considerable interest was circulating tumor DNA detection, sometimes called liquid biopsy (although that term also encompasses circulating tumor cells). A few of the ctDNA presentations are highlighted below.

Read More

Topics: Cancer, Circulating Tumor DNA, immunotherapy

Previewing the American Association for Cancer Research 2016 Conference #AACR16

The premier cancer research conference heads to the New Orleans Convention Center April 17 - 20, 2016

Posted by Dale Yuzuki on Apr 16, 2016 9:00:00 AM

With over “Cancer Moonshot: A Call to Action” 20,000 scientists, the American Association for Cancer Research conference describes itself as a ‘must-attend event for cancer researchers and the broader cancer community’. One sign of the prominence of this event is the fact that US Vice President Joseph Biden will be delivering a special closing address, in connection with the recent announcement of the  announced at the recent World Economic Forum.

Read More

Topics: Cancer, Genomics, cancer research

The FDA NGS-based Oncology Panels Workshop

Impressions from the first FDA workshop focusing on NGS-based oncology diagnostic tests

Posted by Yves Konigshofer on Apr 1, 2016 11:08:00 AM

The U.S. Food and Drug Administration on February 25, 2016 held an all-day public workshop entitled “Next Generation Sequencing-based Oncology Panels” at their White Oak campus in Silver Spring, Maryland. Companion diagnostics were a recurring theme of the initial FDA presentations at this Next Generation Sequencing-Based Oncology Panels Workshop and these important tests will be our focus here. The slides that were presented at the workshop are available (PDF) and are referenced below, and those presented by SeraCare’s CSO Russell Garlick start on page 196.

Read More

Circulating Tumor DNA Reference Materials

The Seraseq Circulating Tumor DNA-I Reference Materials officially launches, as well as a Circulating Tumor DNA-I Mutation Mix

Posted by Dale Yuzuki on Mar 24, 2016 11:07:00 AM

Circulating tumor DNA detection by real-time quantitative PCR, digital PCR, or next-generation sequencing has garnered an abundance of scientific and commercial interest. We have written before about the critical need for standards and reference materials for this emerging translational oncology research and applied domains and we are pleased to report the launch of the Seraseq Circulating Tumor DNA Reference Materials.

Read More

Highlights from the 2016 Molecular Medicine Tri-Conference

Diagnosing inherited disease, processing FFPE samples, state-of-the-art oncology in North Carolina, and developments in circulating tumor DNA technology

Posted by Dale Yuzuki on Mar 22, 2016 11:05:00 AM

We are living through a time of rapid change in the clinical genetics laboratory, though at times it may appear that change doesn’t occur fast enough given the challenges within the existing healthcare system. At the recent Molecular Medicine Tri-Conference held in San Francisco March 7 through 11 2016, here are a few summary highlights of the conference.

Read More

Topics: Cancer, Circulating Tumor DNA, Inherited Disease, Genetics, Genomics, ctDNA, Reference Material, Oncology, Rare Disease

Molecular Tri-Conference Preview (San Francisco CA March 7-11 2016)

A molecular medicine, drug discovery and diagnostics conference recognizing the potential of new technologies and their role in mitigating disease and identifying transformative treatments

Posted by Dale Yuzuki on Feb 29, 2016 10:16:00 AM

The 23rd annual Molecular Medicine Tri-Conference will be in San Francisco, California March 7 through 11, 2016, and will cover topics ranging from personalized diagnostics, circulating tumor cells, and clinical NGS diagnostics through integrated bioinformatics, frontiers in gene editing, cancer immunotherapy and molecular diagnostics for infectious disease.

Read More

Oncology Regulatory Framework for NGS Webinar Friday Feb 26 2016

A webinar co-sponsored by TOMA Biosciences, Intermountain Health and SeraCare

Posted by Dale Yuzuki on Feb 22, 2016 11:02:00 AM

We are living at a time when genomic technologies (in particular next-generation sequencing) are revolutionizing the practice of medicine, in particular in the field of oncology. In addition, the US Food and Drug Administration has made it clear that these advanced technologies as they are applied to diagnostic testing need to come under regulatory oversight.

Read More

Circulating Tumor DNA Poster at Keystone Symposium

Poster Titled “New Technical Approach to Construct ctDNA Materials for use in Characterizing, Developing and Validating Plasma Assays”, available for download

Posted by Dale Yuzuki on Feb 11, 2016 10:57:00 AM

The Keystone Symposia is an organization with 44 years of history on specialized topics across the fields of molecular and cellular biology. This week in Banff, Alberta, Canada is a Keystone Symposia conference called The Cancer Genome, along with a joint meeting on Genomics and Personalized Medicine. Their Twitter description (@KeystoneSymp) describes the Keystone organization as “A catalyst for accelerating life science discovery and connecting scientists within and across disciplines at symposia worldwide”.

Read More

Topics: Cancer Test, Circulating Tumor DNA, Precision Medicine, Variation, Mutation, ctDNA, Test Development, Reference Material, Oncology, SeraSeq

Evaluation-Small

Subscribe for Updates

Categories

see all